SOLICITATION NOTICE
66 -- Miltenyi AutoMACS Pro Separator
- Notice Date
- 8/5/2010
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100160-MM
- Archive Date
- 9/4/2010
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6072, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Pediatric Oncology Branch (POB) plans to procure a brand name AutoMACS Pro Separator manufactured by Miltenyi Biotec, 12740 Earhart Ave., Auburn, CA 95602 This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 334516 and the business size standard in 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The contractor shall provide one autoMACS Pro Starting Kit, accessories, training and installation. Facts and Reasons to Justify Other than Full and Open Competition: Statutory authority: Statute: This acquisition is conducted under the authority of section 4202 of the Clinger-Cohen Act of 1996 as set forth in 13.106-1 (b)(1). (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). No other requirement and/or type for supply or service will satisfy agency need. No other requirement and/or type for supply or service will satisfy agency need. Miltenyi is uniquely qualified to provide validated, proven magnetic cell separators for research use. In addition, they are the preferred platform for clinical scale magnetic cell separation of multiple cell types, a very important consideration for a Branch conduction translational research. Numerous bead-conjugated antibodies are available for both mice and humans making Miltenyi a very flexible platform allowing the consistent separation of large numbers of highly purified cell types. The vast majority of magnetic cell separators sold to the NCI are from Miltenyi Biotec Inc. and the CliniMACS is currently being used for multiple clinical-grade cell separations by the Department of Transfusion Medicine in the NIH Clinical Center. The reasons for this are use of micro-bead technology, consistency of separations and availability of large number of bead-conjugated reagents using this platform allowing for separation of a large variety of cell types. NCI is currently using manual bead separation using Miltenyi reagents within the Pediatric Oncology Branch using single use columns. Since all current magnetic cell separation protocols utilize the Miltenyi platform, switching vendors would put the continuity of research at risk as results from another vendor could be more difficult to interpret in relation to the current Miltenyi-based protocols. The instruments currently rendered by Miltenyi and the now required services are both part of the United States Research Project entitled "Biology and Therapy of T Cell Depletion". It is paramount that this research project's results be scientifically sound and therefore capable of withstanding the greatest amount of scientific question and scrutiny. The only way to insure the consistency and scientific merit of the tests is for them to be performed by the same source as current tests. Minute differences in test results of this kind occur between sources. Those small differences between vendors are enough to compromise the science. Therefore, the vendor who can insure transition from last generation analog instrumentation to current generation digital instrumentation must be used. The following are the unique specifications of the autoMACS Pro Separator: •Barcode reader ("code reader") or touchscreen activated automated cell isolation system with pre-programmed isolation protocols that are utilized by the integrated computer. •Sequential separation and labeling of up to six samples without user intervention for both negative and positive selection. •Six samples can consist of both manually and auto-labeled cells. •Custom cooling sample rack to keep samples cool during the separation process. •Reagents used for auto-labeling are the same as used for manual protocols using MACS reagents. •System uses biodegradable 50 nm super-paramagnetic MicroBeads (iron) coated with polysaccharide that form a colloidal suspension. •MicroBeads are directly conjugated to monoclonal antibodies. •Separation time of 3-10 minutes, depending on the program. •Input volume of 100 ul to 50 ml. •Automated system cleaning. •Patented columns: dual super-paramagnetic, bio-Teflon coated matrix columns that are reusable over a two week period or up to 100 separations, whichever comes first. •High-gradient magnetic field optimized for cell isolation while maintaining optimal cell viability and function. •Sensitivity: highly pure selection and recoveries of every rare population, frequencies down to 10-8. •Instrument has been designed and manufactured. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 20, 2010. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist, at marinome@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100160-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100160-MM/listing.html)
- Record
- SN02230374-W 20100807/100805235535-4c55ea2d222b79b7d47dd65342f1e5bb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |